My favourite UK share on the entire LSE has fallen 5% in a week! Time to buy?

Harvey Jones has waited for years to buy this brilliant UK share. Has the recent stock market dip finally handed him an opportunity to do so?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The recent FTSE 100 dip has knocked what I think could be the best UK share of the lot, pharmaceutical giant AstraZeneca (LSE: AZN)? Is this my chance to buy it at a rare discount?

As a rule, I fight shy of super soaraway stocks like this one. Sod’s law suggests they’ll crash as soon as I clamber on board. So I’ve shunned AstraZeneca for years, only to watch its share price grow and grow.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

There’s a lot of controversy over CEO salaries, but Astra’s Pascal Soriot has more than justified his by doing a brilliant job since joining in October 2012.

At the start of his tenure, the AstraZeneca share price stood at 2,877p. It peaked at 13,274p a few days before the recent bout of volatility. That’s a rise of 360%. All dividends are on top.

Can it keep climbing like this?

AstraZeneca is comfortably the UK’s biggest company, with a market cap of around £195bn. Oil giant Shell is a distant second at just £157bn. I just wish more LSE-listed businesses could scale up like this one.

The momentum has largely continued with the shares up 16.41% in the last 12 months, although they’re down 5.5% over the week. This doesn’t exactly make them cheap though. AstraZeneca still trades at a whopping 43.03 times earnings. That’s way above the FTSE 100 average of around 15 times.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Can I justify buying at that price? AstraZeneca continues to bomb along, with first-half revenue up 18% to $25.6bn. It also upgraded full-year 2024 guidance, forecasting mid-teens percentage growth in total revenue and core earnings per share.

All the hard work Soriot has put into building the company’s drugs pipeline is paying off with interest. And with the world getting older and sicker, that’s likely to continue. AstraZeneca also enjoys healthy 82% margins on core product sales.

It’s a top FTSE 100 income growth stock

There will always be risks to investing in pharmaceutical stocks. Getting drugs to market is a tortuous process, with potential failure at every stage.

Successful blockbuster treatments eventually come off patent, hitting revenues. Plus there’s the constant risk of litigation, particularly in the US, which can trigger legal claims for hundreds of millions of dollars. That can hammer share prices. As I’ve discovered through my holding in FTSE 100 rival GSK.

AstraZeneca’s dividend yield is relatively low at 1.53%, but that’s mostly down to the rocketing share price. Dividend per share growth has been a little bumpy, but the general direction is upwards, as this table shows.


Chart by TradingView

This is clearly a brilliant company. My problem is that wiser investors than me discovered this yonks ago, and have reaped the rewards.

Despite the recent dip, I won’t be buying. My GSK shares are trading at just 10.57 times earnings while yielding 3.54%. I’ll sit tight, cross my fingers and hope they catch up with AstraZeneca.

Like buying £1 for 31p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »